Ramky Infrastructure FY26: order book strength meets a volatile quarter

Ramky Infrastructure Limited ended FY26 with a mix of steady execution and one-off effects that reshaped the headline profit line. On a standalone basis, the company reported revenue of 1,679 crore for FY25-26 and profit after tax of 250 crore plus. It also closed the year with nil term debt and a stated return on equity of 20 percent. The top line reflects a year where quarterly revenue moved in a tighter band than FY25-26 began, but profitability was influenced by an exceptional item. Management has clarified that both PBT and PAT include a gain from the sale of an equity stake in a subsidiary, Visakha Pharma city Ltd.

What stands out more than the quarterly noise is the scale of business secured through the year. Standalone order inflow was 3,000 crore and the order book was 9,500 crore at year-end. On a consolidated basis, order inflow was 6,500 crore and the order book reached 13,000 crore. For an EPC-led infrastructure company, that backlog is the clearest indicator of revenue visibility. It also fits the company’s positioning, built over three decades of experience across DBFOT, EPC, HAM, BTS, BOT and O and M models in sustainable infrastructure.

A portfolio built around industrial and urban infrastructure

Ramky Infrastructure has described its current focus sectors as industrial, water and waste water, and urban solutions. In practice, the investor presentation frames the business through two key verticals.

The industrial vertical spans industrial parks, core infrastructure such as roads, highways, bridges, tunnels and civil works, and operation and maintenance. It also includes end-to-end project development through SPVs and models such as BOT and annuity-based structures. The urban solutions vertical includes 24x7 water supply solutions, smart water metering and tertiary water treatment, and extends into residential and commercial buildings as well as mission-critical data center infrastructure.

The year’s project wins underline that mix. The company highlighted a 3,000 crore Life Sciences City project, a 1,000-hectare development of a high tech pharma park with a 95-year concession period from Maharashtra Industrial Development Corporation at Dighi Port Industrial Area, Maharashtra. The stated revenue streams include land lease premium, development charges, maintenance charges and utilities charges. Alongside this, Ramky won a 2,085 crore HMWSSB water transmission project under the Godavari Drinking Water Supply Scheme, linked to Hyderabad’s long-term water infrastructure and Musi River rejuvenation. It also received a 1,401 crore EPC plus O and M contract from Maharashtra Industrial Township Limited for the Dighi Port Industrial Area project.

This combination matters for investors because it diversifies the earnings profile. Pure EPC execution can be sensitive to working capital cycles and input cost swings. In contrast, development projects and O and M can add annuity-like cash flows if structured well. The company also emphasized a strong business mix with capex and opex, which is consistent with the project list and the way it positions itself.

Standalone performance: stable revenue, uneven profitability

Standalone quarterly revenue in FY25-26 was 354 crore in Q1, 444 crore in Q2, 452 crore in Q3, and 427 crore in Q4. That adds up to the FY26 total of 1,679 crore reported in the presentation. Compared with FY24-25, where quarterly revenue ranged from 430 crore to 550 crore, FY25-26 shows a lower starting point and a more even middle of the year. It signals execution continuity but also points to a softer run-rate versus the prior year’s first half.

The margin line was more volatile. Standalone EBITDA in FY25-26 was 100 crore in Q1, 117 crore in Q2, 103 crore in Q3, and 19 crore in Q4. Q4 is the outlier in the series. PBT was 74 crore in Q1, 95 crore in Q2, 80 crore in Q3, and 149 crore in Q4. PAT was 154 crore in Q1, 154 crore in Q2, 68 crore in Q3, and 57 crore in Q4.

Those profit numbers cannot be read like-for-like across quarters because the company explicitly notes that PBT and PAT include an exceptional gain from the sale of its equity stake in Visakha Pharma city Ltd. That disclosure is important because it suggests that part of the year’s earnings strength came from a transaction rather than operating leverage.

Even so, two messages emerge from the standalone dashboard. First, the company maintained revenue delivery across quarters despite the typical seasonality and execution risks in infrastructure. Second, the balance sheet posture appears conservative, with nil term debt at the standalone level and the presentation highlighting positive cash flow from operations and effective working capital management as part of its competitive advantage.

Consolidated performance: stronger scale, leverage contained

On a consolidated basis, Ramky reported revenue of 1,846 crore for FY25-26 and an order book of 13,000 crore. Consolidated term debt stood at 160 crore and return on equity was 13 percent. Consolidated PAT was also described as 250 crore plus.

Quarterly revenue in FY25-26 was 379 crore in Q1, 471 crore in Q2, 488 crore in Q3, and 507 crore in Q4. Unlike standalone, consolidated revenue shows a clearer step-up through the year, ending with the highest quarter in Q4. That progression aligns with the idea that subsidiaries and consolidated entities added scale or had a different project ramp pattern.

EBITDA improved from the prior year’s volatility. FY24-25 consolidated EBITDA included a negative Q4 of minus 30 crore, while FY25-26 EBITDA was positive in every quarter: 137 crore in Q1, 139 crore in Q2, 137 crore in Q3, and 11 crore in Q4. PBT followed a similar pattern, with FY24-25 ending at minus 35 crore in Q4, while FY25-26 delivered 100 crore in Q1, 107 crore in Q2, 105 crore in Q3, and 40 crore in Q4. PAT in FY25-26 was 77 crore, 76 crore, 78 crore, and 52 crore across the four quarters.

The consolidated view is useful because it places the standalone exceptional gain in context. While the presentation does not break out the exceptional item at the consolidated level, it does show that underlying quarterly profitability was positive through FY25-26, and far less erratic than the prior year’s last quarter.

What the order book is saying about the next cycle

Infrastructure companies are often judged on a simple chain: order wins lead to backlog, backlog converts to revenue, and working capital discipline determines how much of that revenue becomes cash. Ramky’s presentation leans into this framework by pairing order book strength with claims of positive operating cash flow and effective working capital management. It also positions itself as a nil term debt company at the standalone level, which can reduce vulnerability to interest rate movements.

The projects cited in the update section also imply a shift toward larger, multi-year platforms. The Life Sciences City project has a 95-year concession period and multiple stated revenue streams such as land lease premium and utilities charges. While the presentation does not quantify annual cash flows, it signals a development-led model where monetization may extend beyond EPC billing. The two large water and industrial township contracts signal continued relevance in urban utilities and industrial infrastructure, which aligns with the company’s focus sectors.

Competitive advantage in the presentation is framed in three clusters. The first is management capability, growth potential, risk mitigation and order book mix. The second is profitability consistency, positive cash flow from operations, effective working capital management, and nil term debt. The third is technology and innovation. Investors should treat these as intent statements, but they are still useful as a checklist. The next few quarters will likely be judged on whether the order book converts smoothly without margin shocks, and whether the company can keep working capital under control as execution scales.

The quarterly standalone numbers also highlight a practical point. Even with a strong backlog, quarterly EBITDA and profit can swing due to project stage mix, billing milestones, or one-off items. That makes it important to track full-year progress and the quality of earnings. The presentation’s explicit note on the exceptional gain is therefore not a footnote. It is central to reading FY26 profit.

Closing view: backlog-led confidence with an eye on earnings quality

Ramky Infrastructure ends FY25-26 with clear strengths: a large order book on both standalone and consolidated bases, meaningful project awards across industrial development and water transmission, and conservative standalone leverage with nil term debt. Revenue delivery stayed steady through the year, and the consolidated business showed improving quarterly scale.

At the same time, FY26 earnings need to be read with discipline because PBT and PAT include an exceptional gain from the sale of an equity stake in a subsidiary. Investors will want to separate transaction-led profit from operating performance, and watch whether EBITDA normalizes after the weak standalone Q4 print.

The theme for the year is disciplined execution backed by a stronger pipeline. If the company can convert its 9,500 crore standalone and 13,000 crore consolidated order books into predictable revenue while holding working capital and margins steady, the next cycle can be defined less by one-off gains and more by repeatable operating results.